Related Experiment Video

Updated: May 23, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

944

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report

Nikoo Mozafari1,2

  • 1Skin Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.

Clinical Case Reports
|March 7, 2025
PubMed

Insights

New research shows Janus kinase (JAK) inhibitors may effectively treat prurigo nodularis (PN). This case study highlights tofacitinib as a successful treatment for refractory PN, offering hope for patients with this chronic skin condition.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense itching and nodular lesions.
  • Recent understanding of PN pathogenesis points to specific immune pathways, suggesting targeted therapies.

Purpose of the Study:

  • To evaluate the efficacy of Janus kinase (JAK) inhibitors in treating refractory prurigo nodularis.
  • To present a case study of successful PN treatment with tofacitinib.

Main Methods:

  • Literature review on PN pathogenesis and JAK inhibitor mechanisms.
  • Clinical case presentation of a patient with refractory PN.

Main Results:

  • Emerging evidence supports JAK inhibitors as a potential treatment for both atopic and non-atopic PN.
  • Tofacitinib demonstrated successful treatment outcomes in a case of refractory PN.

Conclusions:

  • JAK inhibitors, including tofacitinib, represent a promising therapeutic avenue for managing prurigo nodularis.
  • Targeted therapies offer new hope for patients with difficult-to-treat PN.
Keywords:
JAK inhibitorsbaricitinibprurigo nodularistofacitinibupadacitinib

More Related Videos

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

8.9K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.7K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K